IRCCS Istituto Nazionale Tumori Fondazione Pascale — Sponsor Intelligence | 27 EU Trials

Filter these 27 trials by condition, phase, country and more.

Open in Search →

27 Registered trials

17 Recruiting

5 Completed trials

2 Countries active

43 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 3 Phase II/III: 2 Phase II: 19 Phase I/II: 1 Phase I: 1 Phase I (Other): 1

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Colorectal cancer metastatic 4 Ovarian cancer recurrent 2 ARID1A gene mutation 1 Lung cancer metastatic 1 Ovarian cancer 1 Rectal cancer 1 Gastrooesophageal cancer 1 Prostate cancer 1 Oropharyngeal cancer 1 Pancreatic carcinoma 1 Cholangiocarcinoma 1 Oral neoplasm 1

Top IMPs

OXALIPLATIN 4 FLUOROURACIL 3 IRINOTECAN HYDROCHLORIDE TRIHYDRATE 3 OLAPARIB 3 BLEOMYCIN SULFATE 2 CALCIUM LEVOFOLINATE 2 CISPLATIN 2 LENVATINIB 2 PACLITAXEL ALBUMIN-BOUND 2 PANITUMUMAB 2 AFLIBERCEPT 1 BEVACIZUMAB 1

All trials

27 total

DETECTION RATE AND CLASSIFICATION OF BREAST LESIONS WITH DIGITAL MAMMOGRAPHY WITH CONTRAST MEDIUM (CEDM) ALONE AND IN COMBINATION WITH TOMOS… Pending

2024-519017-62-00 Phase II 1 country IODIXANOL; IOHEXOL; IOPROMIDE
ORGAN SPARING FOR LOCALLY ADVANCED RECTAL CANCER AFTER NEOADJUVANT TREATMENT FOLLOWED BY ELECTROCHEMOTHERAPY - LARC_ DEEP_CANCERS Pending

2024-519050-37-00 Phase II 1 country
Cannabis extrAct in oncology Patients for the treatment of TUmor Related symptom burden (CAPTURE) Pending

2024-519568-42-00 Phase II 1 country DRONABINOL, CANNABIDIOL
A PHASE 2 STUDY OF STRIDE (durvalumab + tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carci… Pending

2025-521608-23-00 Phase II 1 country LENVATINIB
A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36 Pending

2025-522084-15-00 Phase II/III 1 country PACLITAXEL ALBUMIN-BOUND
Inavolisib for PIK3CA mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial Recruiting

2025-522981-61-00 Phase II 1 country INAVOLISIB
Randomized phase 2 study of Simvastatin in patients with ARID1A mutated advanced gastrooesophageal carcinoma treated with Nivolumab and Oxal… Recruiting

2024-519591-39-00 Phase II 1 country CALCIUM LEVOFOLINATE PENTAHYDRATE; NIVOLUMAB; OXALIPLATIN
Pembrolizumab plus Lenvatinib in vulvar cancer patients: The prospective, multi-cohorts and multicentre, phase 2 MITO VULVA-01 study. Recruiting

2023-509180-24-00 Phase II 1 country LENVATINIB; PEMBROLIZUMAB
REDI-CaP (Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients). Innovative Management of Patients with Unfavorable Intermed… Recruiting

2025-521170-33-00 Phase II 1 country RELUGOLIX
Regorafenib as second-line treatment of patients with RAS-mutant advanced colorectal cancer: a multicentre, phase 2 study - STREAM-2 Recruiting

2024-519669-23-00 Phase II 1 country AFLIBERCEPT; CALCIUM LEVOFOLINATE; IRINOTECAN HYDROCHLORIDE TRIHYDRATE; OXALIPLA…
MITO 31- A phase II trial of Olaparib in patients with recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes: The M… Recruiting

2024-516841-38-00 Phase II 1 country OLAPARIB
Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. Th… Recruiting

2024-516842-21-00 Phase III 1 country OLAPARIB
Single microdose trial - CXCR4 PET tracer - Pharmacokinetics and pharmacodynamics of [68Ga]Ga-R54, a CXCR4-targeted radiopharmaceutical in p… Recruiting

2024-513303-14-00 Phase I 1 country
Randomized phase 2 study of Valproic acid combinEd with rechallenge anti-EGFR based regimen regimens in pretreated patients with RAS/BRAF wi… Recruiting

2024-514420-16-00 Phase II 1 country IRINOTECAN HYDROCHLORIDE TRIHYDRATE; PANITUMUMAB
MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, … Recruiting

2024-516839-27-00 Phase II 1 country OLAPARIB
Prospective phase IIb study to evaluate the efficacy of laparoscopic electrochemotherapy in the treatment of locally advanced pancreatic can… Recruiting

2024-519067-17-00 Phase II 1 country BLEOMYCIN SULFATE; CALCIUM LEVOFOLINATE; FLUOROURACIL; IRINOTECAN HYDROCHLORIDE …
Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left … Recruiting

2023-509551-14-00 Phase III 1 country PANITUMUMAB
Neo-adjuvant Chemo and immunotherapy with durvalumab (MEDI4736) and tremelimumab (MEDI1123) In The pre-operAtive Treatment of locally advanc… Recruiting

2024-518656-23-00 Phase II 1 country CISPLATIN; GEMCITABINE
Randomized phase 2 study of Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic P… Recruiting

2024-518710-11-00 Phase II 2 countries PACLITAXEL ALBUMIN-BOUND
NeoAspMet - Neoadjuvant Aspirin and/or Metformin during preoperative induction chemotherapy and chemoradiotherapy for locally-advanced recta… Recruiting

2024-519007-10-00 Phase II/III 1 country
CETUXIMAB, IRINOTECAN AND FLUOROURACILE IN FIRST-LINE TREATMENT OF IMMUNOLOGICALLY-SELECTED ADVANCED COLORECTAL CANCER PATIENTS - the CIFRA … Recruiting

2024-518987-11-00 Phase II 1 country
VshoRT-R3: Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperatIve treatment in low-moderate risk r… Recruiting

2024-513920-40-00 Phase I/II 1 country
A phase I trial of IMA970A plus Montanide in combination with Durvalumab (anti-PD-L1) in patients with very early, early and intermediate st… Ended

2024-518298-33-00 Phase I (Other) 1 country
REVOLUTION - Randomized phasE 2 study of Valproic acid in combination with bevacizumab and Oxaliplatin/fLUoropyrimidine regimens in patients… Ended

2024-516844-25-01 Phase II 1 country BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; OXALIPLATIN; VALPROIC ACID, SODIUM VALP…

Showing 1–24 of 27 trials

← All sponsors A–Z